Palvella Therapeutics Inc/$PVLA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Palvella Therapeutics Inc
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Ticker
$PVLA
Sector
Primary listing
Employees
29
Headquarters
Website
PVLA Metrics
BasicAdvanced
$1.5bn
-
-$4.19
-
-
Price and volume
Market cap
$1.5bn
52-week high
$151.18
52-week low
$20.20
Average daily volume
241k
Financial strength
Current ratio
28.879
Quick ratio
28.728
Long term debt to equity
8.684
Total debt to equity
8.774
Interest coverage (TTM)
-6.86%
Profitability
Management effectiveness
Return on assets (TTM)
-16.60%
Return on equity (TTM)
-34.25%
Valuation
Price to book
6.3
Price to tangible book (TTM)
6.3
Price to free cash flow (TTM)
-41.327
Free cash flow yield (TTM)
-2.42%
Free cash flow per share (TTM)
-2.473
Growth
Earnings per share change (TTM)
-16.98%
PVLA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs